Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR1797281

— · cohortSC

5158e621-3ab1-52d1-84fe-1bac16efddfd

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSC
subtype
cohortSC
age_years
44

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V1+0.560
  • G2M_CHECKPOINT+0.550
  • E2F_TARGETS+0.540
  • PROTEIN_SECRETION+0.470
  • MITOTIC_SPINDLE+0.410
  • INTERFERON_ALPHA_RESPONSE+0.360
  • MTORC1_SIGNALING+0.350
  • UNFOLDED_PROTEIN_RESPONSE+0.350
  • ANDROGEN_RESPONSE+0.320
  • OXIDATIVE_PHOSPHORYLATION+0.310

Top 10 suppressed

  • COAGULATION-0.400
  • KRAS_SIGNALING_DN-0.350
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
  • MYOGENESIS-0.300
  • APICAL_SURFACE-0.290
  • NOTCH_SIGNALING-0.280
  • APICAL_JUNCTION-0.260
  • IL2_STAT5_SIGNALING-0.260
  • WNT_BETA_CATENIN_SIGNALING-0.250
  • INFLAMMATORY_RESPONSE-0.230

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1R135
bladder-landscape@3
——0.848
2SRR13311183
bladder-landscape@3
——0.841
3TCGA-44-7669-01A-21R-2066-07
lung-landscapes@6
—cohortA30.839
4SRR1797282
lung-landscapes@6
—cohortSC0.838
5SRR1797288
lung-landscapes@6
—cohortSC0.838
6fac69f81-0d8c-40a0-8263-b54d5f06d7b3
melanoma-umap@29
——0.836
7TCGA-05-4415-01A-22R-1858-07
lung-landscapes@6
—cohortA40.831
888318
medullo-epn-umap@date-based
EPNSupratentorial EPN0.830
9TCGA-A2-A0YT-01A-11R-A109-07
breast-umap@18
—B0.830
10TCGA-AO-A03O-01A-11R-A00Z-07
breast-umap@18
—C0.825

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V10.560Inavolisib— uncovered
G2M_CHECKPOINT0.550Inavolisib— uncovered
E2F_TARGETS0.540Inavolisib— uncovered
PROTEIN_SECRETION0.470Remibrutinib— uncovered
MITOTIC_SPINDLE0.410Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.360Inavolisib— uncovered
MTORC1_SIGNALING0.350Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.350Idelalisib— uncovered
ANDROGEN_RESPONSE0.320Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.310Remibrutinib— uncovered
MYC_TARGETS_V20.290Idelalisib— uncovered
PANCREAS_BETA_CELLS0.280Cobimetinib— uncovered
PEROXISOME0.240Idelalisib— uncovered
FATTY_ACID_METABOLISM0.220Inavolisib— uncovered
SPERMATOGENESIS0.220Inavolisib— uncovered
DNA_REPAIR0.210Idelalisib— uncovered
UV_RESPONSE_DN0.200Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.190Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.150Idelalisib— uncovered
BILE_ACID_METABOLISM0.140Inavolisib— uncovered